Alkermes is morphing from a royalty “cash house” into a leveraged sleep-and-neuroscience operator—where Lybalvi and LUMRYZ build the floor and ALKS 2680 supplies the blockbuster ceiling.
Overview
Alkermes is undergoing the most consequential pivot in its 30-year history: moving from a diversified drug delivery/royalty company (“royalty house”) to a focused, fully integrated neuroscience biopharma. This transition is driven by (i) the 2023 spin-off of Mural Oncology, (ii) the expiration of the high-margin Invega Sustenna royalty stream in Aug 2024 and ongoing decay of remaining Invega-related revenues, and (iii) an aggressive, transformative late-2025 acquisition of Avadel to obtain LUMRYZ and establish a sleep medicine franchise. The company’s value proposition has shifted from steady, high-margin royalties to a growth-and-execution story centered on owned brands and pipeline outcomes. In 2025, proprietary products grew strongly (portfolio +16% YoY in Q3), led by Lybalvi (+32% YoY), enabling management to raise full-year revenue guidance to $1.43–$1.49B despite a sharp drop in manufacturing/royalty revenue. The key change in risk is capital structure: funding Avadel requires ~ $1.5B of debt, moving Alkermes from net cash to net debt, making execution, integration, and clinical safety (ALKS 2680) central to the equity narrative.